Endo International PLC said two executives will leave the company following a reorganization, and it made two appointments in its branded drug business.
Chief Scientific Officer Susan Hall, who oversaw global research and development, will serve as a consultant on the Xiaflex cellulite treatment after her departure in March 2017, the Dublin-based company said in a Dec. 21 news release. Joseph Ciaffoni, the president of the branded pharmaceuticals unit in the U.S., will depart "in light of the significant organizational restructuring that has taken place," Endo said.
The drugmaker chose Patrick Barry as senior vice president of U.S. branded pharmaceuticals, effective immediately, Endo said. Barry will oversee all commercial activities for U.S. branded medicines, including strategy, new product planning, marketing and sales. Matthew Davis will become senior vice president of R&D for branded pharmaceuticals as of Jan. 3, 2017, the company said.
Barry most recently was general manager and head of North America general medicines for Sanofi. Davis most recently was the chief medical officer for Lupin Ltd. unit Lupin Pharmaceuticals Inc.